| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-10-05 | RA CAPITAL MANAGEMENT, L.P. | director, 10%+ owner | Award | 10,700 | — | — |
| 2026-10-05 | RA CAPITAL MANAGEMENT, L.P. | director, 10%+ owner | Award | 64,000 | $3.75 | $240K |
| 2026-10-05 | Verdine Gregory L. | director | Award | 10,700 | — | — |
| 2026-10-05 | Verdine Gregory L. | director | Award | 64,000 | $3.75 | $240K |
| 2026-10-05 | Tan Aik Na | director | Award | 10,700 | — | — |
| 2026-10-05 | Tan Aik Na | director | Award | 64,000 | $3.75 | $240K |
| 2026-10-05 | TAKANASHI KEN | director | Award | 10,700 | — | — |
| 2026-10-05 | TAKANASHI KEN | director | Award | 64,000 | $3.75 | $240K |
| 2026-10-05 | CORRIGAN MARK | director | Award | 10,700 | — | — |
| 2026-10-05 | CORRIGAN MARK | director | Award | 64,000 | $3.75 | $240K |
| 2026-10-05 | Rawcliffe Adrian | director | Award | 10,700 | — | — |
| 2026-10-05 | Rawcliffe Adrian | director | Award | 64,000 | $3.75 | $240K |
| 2026-10-05 | Wagner Heidi L | director | Award | 10,700 | — | — |
| 2026-10-05 | Wagner Heidi L | director | Award | 64,000 | $3.75 | $240K |
| 2026-10-05 | HENRY CHRISTIAN O | director | Award | 10,700 | — | — |
| 2026-10-05 | HENRY CHRISTIAN O | director | Award | 64,000 | $3.75 | $240K |
| 2026-08-12 | Rawcliffe Adrian | director | Sale | 12,700 | $5.29 | $67K |
| 2026-08-11 | Wagner Heidi L | director | Option exercise | 7,000 | $5.97 | $42K |
| 2026-08-11 | Wagner Heidi L | director | Sale | 7,000 | $6.01 | $42K |
| 2026-08-11 | TAKANASHI KEN | director | Sale | 3,864 | $6.01 | $23K |
| 2026-08-11 | Tan Aik Na | director | Sale | 432 | $6.01 | $3K |
| Filed | Form | Filer | Stake | Shares | |
|---|---|---|---|---|---|
| 2024-10-01 | SC | RA CAPITAL MANAGEMENT, L.P. | — | — | view → |
| 2022-08-12 | SC | Shin Nippon Biomedical Laboratories, Ltd. | — | — | view → |
| 2022-07-20 | SC | Kagoshima Shinsangyo Sousei Investment Limited Partnership | — | — | view → |
| 2021-11-12 | SC | RA CAPITAL MANAGEMENT, L.P. | — | — | view → |
| 2021-08-18 | SC | RA CAPITAL MANAGEMENT, L.P. | — | — | view → |
| 2019-02-20 | SC | Shin Nippon Biomedical Laboratories, Ltd. | — | — | view → |
| 2019-01-28 | SC | RA CAPITAL MANAGEMENT, LLC | — | — | view → |
| 2018-04-26 | SC | Shin Nippon Biomedical Laboratories, Ltd. | — | — | view → |
| 2018-03-22 | SC | Kagoshima Shinsangyo Sousei Investment Limited Partnership | — | — | view → |
| Filed | Form | Issuer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-09-22 | SCHEDULE 13G | BetterLife Pharma Inc. | — | — | view → |
| 2026-09-21 | SCHEDULE 13D/A | SIONNA THERAPEUTICS, INC. | 14.30% | 6,476,193 | view → |
| 2026-09-17 | SCHEDULE 13D/A | TYRA BIOSCIENCES, INC. | — | 14,130,492 | view → |
| 2026-09-03 | SCHEDULE 13G | JATT III Acquisition Corp | — | — | view → |
| 2026-08-17 | SCHEDULE 13G | Latigo Biotherapeutics, Inc. | — | — | view → |
| 2026-08-14 | SCHEDULE 13D/A | SEPTERNA, INC. | — | 5,525,324 | view → |
| 2026-08-10 | SCHEDULE 13D/A | SAB Biotherapeutics, Inc. | — | 9,609,852 | view → |
| 2026-07-23 | SCHEDULE 13D/A | ARTIVA BIOTHERAPEUTICS, INC. | — | 18,415,956 | view → |
| 2026-07-22 | SCHEDULE 13D/A | Freenome, Inc. | — | 15,367,270 | view → |
| 2026-07-21 | SCHEDULE 13D/A | VOR BIOPHARMA INC. | — | 12,937,855 | view → |
| 2026-07-20 | SCHEDULE 13G | Agenus Inc. | — | — | view → |
| 2026-07-07 | SCHEDULE 13D/A | Climb Bio, Inc. CLYM | 33.00% | 23,249,186 | view → |
| 2026-07-02 | SCHEDULE 13D/A | WEREWOLF THERAPEUTICS, INC. HOWL | 4.10% | 1,985,541 | view → |
| 2026-06-26 | SCHEDULE 13D/A | WEREWOLF THERAPEUTICS, INC. HOWL | 6.00% | 2,915,742 | view → |
| 2026-06-24 | SCHEDULE 13D/A | SOLID BIOSCIENCES INC. SLDB | — | 12,036,126 | view → |
| 2026-06-22 | SCHEDULE 13D/A | WEREWOLF THERAPEUTICS, INC. HOWL | — | 3,654,307 | view → |
| 2026-06-18 | SCHEDULE 13D | Parabilis Medicines, Inc. PBLS | 23.80% | 28,933,371 | view → |
| 2026-06-15 | SCHEDULE 13D/A | WEREWOLF THERAPEUTICS, INC. HOWL | — | 5,138,703 | view → |
| 2026-06-15 | SCHEDULE 13D/A | ARTIVA BIOTHERAPEUTICS, INC. ARTV | 36.60% | 17,811,623 | view → |
| 2026-06-03 | SCHEDULE 13G | Editas Medicine, Inc. EDIT | — | — | view → |
Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.
See pricing →